Xtandi Side Effects
Generic name: enzalutamide
Medically reviewed by Drugs.com. Last updated on May 13, 2022.
Note: This document contains side effect information about enzalutamide. Some dosage forms listed on this page may not apply to the brand name Xtandi.
Common side effects of Xtandi include: upper respiratory tract infection, headache, hot flash, laryngitis, nasopharyngitis, pharyngitis, rhinitis, and sinusitis. Other side effects include: lower respiratory tract infection, pneumonia, pulmonary infection, altered mental status, amnesia, bronchitis, cognitive dysfunction, falling, hypertension, hypoesthesia, and memory impairment. Continue reading for a comprehensive list of adverse effects.
Applies to enzalutamide: oral capsules or tablets.
Side effects include:
Adverse effects reported in ≥10% of patients and at an incidence that is ≥2% higher than that reported with placebo: Asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, hypertension. Laboratory abnormalities reported in ≥5% of patients and at an incidence that is >2% higher than that reported with placebo: Leukopenia, neutropenia, hyperglycemia, hypermagnesemia, hyponatremia, hypercalcemia.
Adverse effects reported in ≥10% of patients and at an incidence that is ≥ 2% higher than that reported with bicalutamide: Asthenia/fatigue, musculoskeletal pain, hot flush, hypertension, diarrhea, upper respiratory tract infection, decreased weight.
For Healthcare Professionals
Applies to enzalutamide: oral capsule, oral tablet.
Common (1% to 10%): Spinal cord compression and cauda equina syndrome, paresthesia, hypoesthesia, dysgeusia, restless legs syndrome
Uncommon (0.1% to 1%): Seizures
Postmarketing reports: Posterior reversible encephalopathy syndrome (PRES) (e.g., seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension)[Ref]
Postmarketing reports: Rash[Ref]
Common (1% to 10%): Gynecomastia[Ref]
Very common (10% or more): Constipation (23%), diarrhea (22%)
Common (1% to 10%): Hematuria, pollakiuria
Common (1% to 10%): Hematuria, pollakiuria[Ref]
Very common (10% or more): Neutropenia (15%)
Common (1% to 10%): Thrombocytopenia
Frequency not reported: Leukopenia[Ref]
Very common (10% or more): ALT elevations (10%)
Common (1% to 10%): Bilirubin elevations[Ref]
Very common (10% or more): Decreased appetite (19%), decreased weight (12%)[Ref]
Very common (10% or more): Back pain (29%), arthralgia (21%), musculoskeletal pain (15%)
Common (1% to 10%): Muscular weakness, musculoskeletal stiffness[Ref]
Very common (10% or more): Asthenia/fatigue (51%), falls (13%)
Common (1% to 10%): Fall-related injuries[Ref]
Very common (10% or more): Upper respiratory tract infection (16%), dyspnea (11%)
Common (1% to 10%): Lower respiratory tract and lung infection, epistaxis[Ref]
Postmarketing reports: Face edema, tongue edema, lip edema, pharynx edema[Ref]
Postmarketing reports: Blindness and other visual disturbances due to posterior reversible encephalopathy syndrome (PRES)[Ref]
Frequently asked questions
- Why has it stopped working and what do I take next?
- How long does it work for?
- Xtandi vs Zytiga: How do they compare?
- Erleada vs. Xtandi: What's the difference?
- Does it lower prostate-specific antigen (PSA)?
- Is this a chemotherapy drug and how does it work?
- What is it used for?
More about Xtandi (enzalutamide)
- Check interactions
- Pricing & coupons
- Reviews (17)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
Related treatment guides
1. "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc (2012):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.